Market Overview

CEL-SCI Says Interim Review of Ongoing Phase 3 Trial Showed No safety Concerns

Related CVM
CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review to be important since studies have shown that up to 30% of Phase III trials fail due to safety considerations and the IDMC's safety findings from this interim review were similar to those reported by investigators during CEL-SCI's Phase I-II trials. Ultimately, the decision as to whether a drug is safe is made by the FDA based on an assessment of all of the data from a trial.

Posted-In: News FDA


Related Articles (CVM)

View Comments and Join the Discussion!